{"name":"Biomedical Advanced Research and Development Authority","slug":"biomedical-advanced-research-and-development-authority","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"BioThrax","genericName":"BioThrax","slug":"biothrax","indication":"Other","status":"marketed"},{"name":"Atropine Sulfate Ophthalmic Solution","genericName":"Atropine Sulfate Ophthalmic Solution","slug":"atropine-sulfate-ophthalmic-solution","indication":"Other","status":"marketed"},{"name":"VN","genericName":"VN","slug":"vn","indication":"Prevention of Venezuelan equine encephalitis","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AV7909","genericName":"AV7909","slug":"av7909","indication":"Prophylaxis of anthrax infection in at-risk populations","status":"phase_3"}]}],"pipeline":[{"name":"AV7909","genericName":"AV7909","slug":"av7909","phase":"phase_3","mechanism":"AV7909 is an anthrax vaccine that stimulates immune responses against anthrax toxins through a combination of protective antigen and adjuvant components.","indications":["Prophylaxis of anthrax infection in at-risk populations","Post-exposure prophylaxis following anthrax exposure"],"catalyst":""},{"name":"BioThrax","genericName":"BioThrax","slug":"biothrax","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Atropine Sulfate Ophthalmic Solution","genericName":"Atropine Sulfate Ophthalmic Solution","slug":"atropine-sulfate-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VN","genericName":"VN","slug":"vn","phase":"marketed","mechanism":"Venezuelan equine encephalitis virus (VEEV) vaccine is a live, attenuated vaccine that stimulates an immune response against VEEV.","indications":["Prevention of Venezuelan equine encephalitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOQmxSVS13QmZkMlhNc2FtRE5yMy1RaEc2YVdZQ08zZUtwZkhyN1hLc3NJOTdVd3JTZjJ1MTVFQTFScGltTElwc3d0ZkhCUUlEckN3emY4OURjeERwd0s1WDFyMXU0TVB5TmUxWUU4azZ3eXh0aVNsQXRKOW1odUxBYWlOLVZPN2VnQnROb29mMF9SQ3lzZms0ZXdZMWhqYmtMdXNJ?oc=5","date":"2026-04-08","type":"pipeline","source":"Fierce Pharma","summary":"Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant - Fierce Pharma","headline":"Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNNV9RV3JycWZaNkcyR0lpaFpMSUpiSXdJdTVhU3YzLVZkX1BJbnJZUExkTnhZQmNnRmpxZThnSjZRQjVSeUE4UGRoM2dQVkZsTEJ6OUxtNEJNSjFvbmhrNjVQTFNGUEEzVi1IdC1VdGlZN1pKOVpTbTZfRlJDbENleW9jRFQtUGtBT0tXWDZrWXN5U3NY?oc=5","date":"2026-03-31","type":"pipeline","source":"Pharma Voice","summary":"mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts - Pharma Voice","headline":"mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-13","type":"trial","source":"GlobeNewswire","summary":"Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligibl","headline":"Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Upd","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNTUd2ZE9tdk5xMUpuVjNOLTZFZ0xHUm9SODRVUjcyWUlUQ19QTTZPMDgzVThHZnBIYlZ6Q0V5bFhIVHVGVm1WMFNlRGdUZTdmUlc3SXVNcHZIcTlCNXlyZkNYTHloekFDc3gxT3kwVlhHWTdSVU9CZFl4Y1dKOS1pMk1rVnF2QTU1S0xvTlJxXzFray05N0hhYTREQUxoRExyWkhtajJVRnVST1JRYm5kREx2dXdjWGlaT0N5LWNPUXVPb2lyX1pV?oc=5","date":"2025-10-03","type":"pipeline","source":"Fierce Pharma","summary":"Cidara snares up to $339M from BARDA to bankroll its non-vaccine flu candidate - Fierce Pharma","headline":"Cidara snares up to $339M from BARDA to bankroll its non-vaccine flu candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOWjdBNm45NUMtOGlPVWFRWUhwazNROERXS1Uyczh3Mk0yTTJDeWJvWDg1a1ZLbVF3V21fNTlKdWFMekI5SHlMRWtfRml1TXNxOFBBTGFOWXpjR1Q2Y0daUklrYVBQV2pOQ1lnNWRBNGhGUGZFY3NjR09QTTFpSEI3NzhqWnhhVHFDVGZIYWt3?oc=5","date":"2025-09-30","type":"pipeline","source":"Contract Pharma","summary":"Orexo US Awarded $8M in Funding by BARDA - Contract Pharma","headline":"Orexo US Awarded $8M in Funding by BARDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQeUtubmQtU0VvOEN4SkJkQU9wYlFMMHpJTV9VN1ZZSUhvRU1XUG5WME96MmZucWN1RE1Id0ZUcVc0ZTF2UllmM3NhREpJLVpYN1lWeGVDaTBUMkVpTFlITHVBZ1M5dlVCb0RNWW1fNVpBZ1FkcmlTblFvSDNPNW9pT2pyTGtYbjBhMTh0Ylc3OFdyc3c1ODl4T1VMbWxOR21lR1JHUnFtSWRpYTdlYWR5Tk80a3hGNHN4V0pQblpsNEE?oc=5","date":"2025-08-06","type":"pipeline","source":"Reuters","summary":"US health agency to wind down mRNA vaccine development - Reuters","headline":"US health agency to wind down mRNA vaccine development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPbGxydjZxRUphTTBpY1RGM3NUeUNQS1ZyNi1FVkRYaVdqZ2diZ0RVOXBaYUZGTEdIRXFqVjdPTHRscE9FOFByaE5OREdRcFM3ZnpaeGE1Z1pvM0FhX1NsamJITENNclRhUjdESkxnckF6YkcwclFVVEpKOHZlMExYSGI5RVZFMjg?oc=5","date":"2025-08-06","type":"pipeline","source":"BioSpace","summary":"RFK Jr. Axes 22 mRNA Vaccine Projects Under BARDA - BioSpace","headline":"RFK Jr. Axes 22 mRNA Vaccine Projects Under BARDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5VWTNDMUYtbUJJVXJnc2JfREpwSExUT1VYWUppUXVTS2tqNG5KVmZjV3RNLXFiQ2hLTTAyd0ViR2Q3QmQ2UGtYM1BHTXRHSWdxbUczV2xRSm1jYnBYNUFvblM0aWVNSExGU0cyU1pCT0Q3QkE3UGo1dVRpdw?oc=5","date":"2025-08-06","type":"pipeline","source":"pharmaphorum","summary":"RFK Jr cancels $500m in funding for mRNA vaccines - pharmaphorum","headline":"RFK Jr cancels $500m in funding for mRNA vaccines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNOVlfU0xNTy1BSVJLUHZvNHRMWGV3VFl2VXhzbHRYU2tTZ0FXWVBKTTFoOXRTdkFXbGZENlNFVDNLOFgzOXhIQklpdXllcHdNN0s2SlRHcWVRVTI3UklWUE1HY0xoekpucVRsdFQwbWJzaV9ENkZ3aWxTRFdqN2NsSTAwV0lCeU1ORnc4V2FpTXBFeTVoN2dYd0JUNkJUS3VUMzRpZTlaUHZRZw?oc=5","date":"2025-08-06","type":"pipeline","source":"European Pharmaceutical Review","summary":"mRNA vaccine research worth $500m cut by RFK Jr - European Pharmaceutical Review","headline":"mRNA vaccine research worth $500m cut by RFK Jr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQaFhRTUV2Vk1jb0NXZU52SnBSVEwwNmdNNUZmbC1XV2VaNG1vM0RuMW1faUZ1UFprSHB3M2prNDZvUHFiZzVQdVVGOFdiWHVaN2xZQUJHSWJuc2l3X2xPV1hCbS1jMzFzM0EtNkpnNlBwSjRXTjZaMndScDNYanR4OEFlcFFlYmlkSzljMkotcHlSM1lFZnVTQzFMVlE1eHJ5d09rZEg0NGRSUDZRY0JhZnQ5OUhIQQ?oc=5","date":"2025-08-06","type":"pipeline","source":"TechTarget","summary":"HHS ends $500M in BARDA‑funded mRNA vaccine developments - TechTarget","headline":"HHS ends $500M in BARDA‑funded mRNA vaccine developments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE4yUFFiQ2wwUzYtbk52c2Z2R0lCb3RJUmpVVDM1U1VPRVRQc0dqZjVHRDlSNjdjNnJnOWlGVXNNWmNKZzQ3ZktFZ3BWWldKdXJQMkRz?oc=5","date":"2025-08-05","type":"pipeline","source":"FirstWord Pharma","summary":"HHS pulls funding from 22 mRNA vaccine projects - FirstWord Pharma","headline":"HHS pulls funding from 22 mRNA vaccine projects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPT1lGeVgtSVFyRXBHUmMtZzlzX0JGdldnOU5uYkM0OTA1eXdEd3QwQUpPbm5IZVEwd1JSbHM4UkxCMGlMajMxekJtSU8zZTZDak1tSWk1S25MSW13NkxBRWEyTm5aR0hyT3BQUmpWd1BGN3EtWmViLWxuY1IwZEN2NkFrckhaX3h5TThDZFJQYWFUWDBid2c?oc=5","date":"2025-08-05","type":"pipeline","source":"Fierce Biotech","summary":"HHS winds down mRNA vaccine development funded by BARDA - Fierce Biotech","headline":"HHS winds down mRNA vaccine development funded by BARDA","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":1,"marketed":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}